Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04322292 | A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma | PHASE1 | COMPLETED | 9 | — | — | Sep 12, 2019 | Sep 22, 2022 | Feb 11, 2026 | 1 | China |
The incidence of treatment-emergent adverse events (TEAEs)
| Arm | Type | Description |
|---|---|---|
| C-CAR088 | EXPERIMENTAL | Lymphocytes will be transduced with lentiviral vector containing CAR-BCMA gene. |
| Name | Type | Description |
|---|---|---|
| C-CAR088 | DRUG | Autologous BCMA-directed CAR-T cells, single infusion intravenously at a target dose of 1.0-9.0 x 10\^6 anti-BCMA CAR+T cells/kg. Other Name: CBM.BCMA Chimeric Antigen Receptor T cell. |
Inclusion Criteria: 1. Age 18-75 years old, male or female; 2. The patient volunteered to participate in the study, and he or his legal guardian signed the Informed Consent; 3. Meet the internationally accepted Criteria for the diagnosis of multiple myeloma (IMWG diagnostic criteria 2014); 4. Patie...